Hui Zhao, Doctor
Puhe Biopharma
2
0
0
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (2)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Li Yong Wang, M.D.
The Central Hospital of China Aerospace Corporation
Shared therapeutic areas:
Qifu Li, phD
First Affiliated Hospital of Chongqing Medical University
Shared therapeutic areas:
Harlan M Krumholz, M.D., S.M.
Yale University
Shared therapeutic areas:
Min Kong, M.D.
The 85th Hosptial of P.L.A
Shared therapeutic areas:
Charles Conway, MD
Washington University School of Medicine
Shared therapeutic areas:
Zhen Jun Wang, M.D.
Beijing Chao Yang Hospital
Shared therapeutic areas:
Corinne Levy
Association Clinique Thérapeutique Infantile du val de Marne
Shared therapeutic areas:
Chang Shun Wang, M.D.
Beijing Anorectal Hospital
Shared therapeutic areas:
Doris M Hexsel, MD
Brazilian Center for Studies in Dermatology
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (2)
Showing 2 of 2 trials
Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
All 2 trials loaded